Focus on: Tirzepatide (Mounjaro) for weight management in General Practice
We are pleased to announce that Shaba, Chair of Avon LMC, has written the guidance with the hat of BMA’s role. It has been published on BMA website.
From 23 June 2025, Tirzepatide must be implemented in primary care. Tirzepatide represents a new therapy for weight management, but requires structured implementation, appropriate monitoring, and clarity around responsibilities. GPs should engage in prescribing where clinically appropriate and safely resourced to do so.
GPC England has produced a Focus on Tirzepatide (Mounjaro) for weight management in General Practice document, which explains how Tirzepatide is used, commissioning arrangements (responsibility for funding lies with ICBs), and responding to information requests from private providers.
The guidance also includes a template letter for practices to respond to requests for medical information following a private consultation.
Related Posts
Seasonal Vaccinations Site Campaign Guide AW24
NHS England has published The Seasonal Vaccinations Site Campaign Guide for AW24 that outlines the key guidance and activities required…
Data Security Protection Toolkit (DSPT) for 2024-25
Why complete a DSPT assessment? All organisations that have access to NHS patient information must provide assurances that they have…